JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: A European Leukemia Net (ENL) study

American Journal of Hematology

Volumn 85, Issue 5, 2010, Pages 383-386

  Rinaldi, Ciro R ^a   Rinaldi, Paola ^a   Gemei, Marica ^a   Grimaldi, Francesco ^a   Battipaglia, Giorgia ^a   Vecchio, Luigi Del ^a   Martino, Bruno ^b   Specchia, Giorgina ^c   Candoni, Anna ^d   Gugliotta, Luigi ^e   Vannucchi, Alessandro M ^f   Barbui, Tiziano ^g   Pane, Fabrizio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Hospital of Reggio Calabria   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

^e Arcispedale Santa Maria Nuova ^*  (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; INTERFERON; JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; EUROPE; FEMALE; FLOW CYTOMETRY; GRANULOCYTE PRECURSOR CELLS; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS;

EID: 77951576506     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21687     Document Type: Article

References (20)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061. (Pubitemid 40386783)
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790. (Pubitemid 40570926)
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397. (Pubitemid 40544655)
5. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006;108:1865-1867. (Pubitemid 44394995)
6. Veneri D, Capuzzo E, de Matteis G, et al. Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. Blood Transfus 2009;7:204-209.
7. Schnittger S, Bacher U, Kern W, et al. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): A comparative study on 1103 CMPD and 269 AML cases. Leukemia 2007;21: 1843-1845.
8. Rossi D, Deambrogi C, Capello D, et al. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 2006;135:267-268. (Pubitemid 44401627)
9. Panovska-Stavridis I, Cevreska L, Ivanovski M, et al. JAK2V617F mutations in myeloid malignancies: Single center experience. Prilozi 2009;29:257-268.
10. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006;108:3548-3555.
11. Frohling S, Lipka DB, Kayser S, et al. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood 2006;107:1242-1243. (Pubitemid 43156337)
12. Hsiao HH, Yang WC, Liu YC, et al. Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient. Leuk Res 2008;32:1323-1324.
13. Iwanaga E, Nanri T, Matsuno N, et al. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia. Haematologica 2009;94:433-435.
14. Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25:1434-1436.
15. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007;110:375-379. (Pubitemid 47026857)
16. Zhang SJ, Li JY, Zhang JF, et al. The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis. Leuk Res. 2009;33:e116-e118.
17. Hussein K, Bock O, Theophile K, et al. JAK2 (V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 2009;37:1186-1193.
18. Beer PA, Delhommeau F, Lecouedic JP, et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2009; [Epub ahead of print].
19. Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25:1434-1436.
20. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: Order out of chaos. Cancer 2009;115:3842-3847.